NOX2

Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM•854 Clinical Study, Against High Blood Pressure

Retrieved on: 
Monday, January 30, 2023
Health, Clinical Trials, Research, Science, Pharmaceutical, Cardiology, Biotechnology, NOX2, Lipid, Cell, Oxidative stress, AMF, INSIGHT, Phase, Metabolomics, Radical, DSM-IV codes, American Heart Association, European Society of Cardiology, Executive Committee, Risk, Volunteering, Blood pressure, PEA, Human, Blood, Fibrinogen, BPI, Endothelium, NAFL, European Regional Development Fund, ERDF, White, Serum, Cardiovascular disease, Research and development, AHA, Development, Translational research, Metabolism, Inflammation, MCP-1, ESC, Discovery, Hypertension, Popular Executive Committee of Valencia, Disease, European, Pharmaceutical industry, Dietary supplement, Europe 1

Damage to the vascular wall is a major mechanism in the progression of high blood pressure.

Key Points: 
  • Damage to the vascular wall is a major mechanism in the progression of high blood pressure.
  • This first-in-human evidence confirms the relevance of TOTUM•854's positioning in the early stages of the disease and bodes well for the ongoing Phase II/III clinical efficacy studies in high blood pressure."
  • Mode of action tests also revealed a reduction in angiotensin I-converting enzyme (ACE1) activity, an enzyme well known in the pathophysiology of high blood pressure.
  • 3The fraction of blood remaining after all blood cells (red blood cells, leukocytes, platelets) and fibrinogen (a protein involved in coagulation) have been removed.

Peroxitech Announces Closing of $25M Series A Financing to Develop Novel Treatment for Acute Lung Injury

Retrieved on: 
Tuesday, December 13, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Fund, NIH, Probability, Innovation, Research and development, Development, IND, Partnership, Research, PCI, Patient, Proning, Inc., HIV disease progression rates, CMC, Investment, University, NOX2, ALI, Organization, Pharmaceutical industry, Management

Peroxitech Inc., an emerging biopharmaceutical company developing a novel peptide for treating acute lung injury (ALI), announced the successful completion of a Series A financing round of $25 million led by the Perceptive Xontogeny Venture Fund (PXV Fund).

Key Points: 
  • Peroxitech Inc., an emerging biopharmaceutical company developing a novel peptide for treating acute lung injury (ALI), announced the successful completion of a Series A financing round of $25 million led by the Perceptive Xontogeny Venture Fund (PXV Fund).
  • Peroxitechs lead asset mechanism leverages the discovery of a novel signaling pathway, NOX2, related to the oxidative injury cascade, which has demonstrated broad protection and rescue in several preclinical models.
  • The Companys novel peptide shows it can protect cells from injury and enables injured ones to recover to near normal levels.
  • Peroxitech Inc. is a privately held biopharmaceutical company focused on the development and commercialization of a novel therapeutic for treatment of acute lung injury.

Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator

Retrieved on: 
Wednesday, September 22, 2021
MELAS, ADV, CNS, Therapy, Securities Act of 1933, Neurodegeneration, CD40, CGMP, NOX2, Alzheimer's disease, TNF, Pathology, Neuroinflammation, Traffic barrier, Physiology, LinkedIn, Biomarker, GFAP, Cognitive deficit, CIAS, Nitric oxide, Twitter, NO, Government budget balance, Pharmacology, Mitochondrial encephalomyopathy, Journal, Cognition, Research, CYCN, Drug development, Journal of Neuroinflammation, Securities Exchange Act of 1934, Nasdaq, Translational medicine, SEC, SGC, GLOBE, Disorder, Dietary supplement, Medical imaging

These data suggest that CNS penetrant sGC stimulators, such as Cyclerion development candidates CY6463 and CY3018, could provide therapeutic benefit to individuals living with CNS diseases associated with neuroinflammation.

Key Points: 
  • These data suggest that CNS penetrant sGC stimulators, such as Cyclerion development candidates CY6463 and CY3018, could provide therapeutic benefit to individuals living with CNS diseases associated with neuroinflammation.
  • CY6463 is the first brain-penetrant sGC stimulator to be developed as a symptomatic and potentially disease-modifying therapy for serious CNS diseases.
  • Cyclerion is advancing novel, first-in-class, CNS-penetrant, sGC stimulators that modulate a key node in a fundamental CNS signaling pathway.
  • The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad range of CNS diseases.